An ascending multiple-dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAM-315 administered orally to healthy young adult and elderly subjects

Trial Profile

An ascending multiple-dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAM-315 administered orally to healthy young adult and elderly subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs SAM 315 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jan 2008 The expected completion date for this trial is now 1 Apr 2008.
    • 24 Jul 2007 Status changed from initiated to recruiting.
    • 21 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top